7-氯-4,5-二氢-1H-苯并[E][1,4]二氮杂-2(3H)-酮 | 258850-08-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 7-氯-4,5-二氢-1H-苯并[E][1,4]二氮杂-2(3H)-酮
• 英文名称: 7-chloro-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one
• 英文别名: 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3,4,5-tetrahydro-；7-chloro-1,3,4,5-tetrahydro-1,4-benzodiazepin-2-one
• CAS: 258850-08-7
• 化学式: C₉H₉ClN₂O
• 分子量: 196.636
• InChiKey: GPRMHDRJRXITMD-UHFFFAOYSA-N

物化性质

• 沸点：
  398.1±42.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-氯-4,5-二氢-1H-苯并[E][1,4]二氮杂-2(3H)-酮 在 劳森试剂 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 37.5h， 生成 tert-butyl 8-chloro-1-(2-(pyridin-2-yl)-2-azaspiro[3.3]heptan-6-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine-5(6H)-carboxylate
  参考文献：
  名称：

  [EN] 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS
  [FR] DÉRIVÉS DE 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZÉPINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR V1A POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHOLOGIQUES

  摘要：

  式（I）的化合物对抗加压素受体，特别是Via受体。这些化合物可用于治疗神经心理障碍，如焦虑、抑郁和精神分裂症。优选化合物为1-(2-azaspiro[3.3]heptan-6-yl)-5,6-二氢-4H-苯并[f][1,2,4]三唑并[4,3-a][1,4]二氮杂环己烷衍生物。

  公开号：

  WO2018226769A1
• 作为产物：
  描述：

  2-氨基-5-氯苯腈 在 lithium aluminium tetrahydride 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 22.0h， 生成 7-氯-4,5-二氢-1H-苯并[E][1,4]二氮杂-2(3H)-酮
  参考文献：
  名称：

  Preparation of triazolobenzodiazepine derivatives as Vasopressin V1a antagonists

  摘要：

  This Letter describes the synthesis of a number of fused tricyclic and bicyclic triazolobenzodiazepines for the Vasopressin Via antagonist programme. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.08.011

文献信息

• [EN] 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS<br/>[FR] DÉRIVÉS DE 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZÉPINE ET COMPOSÉS APPARENTÉS SERVANT D'ANTAGONISTES DE LA VASOPRESSINE POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHOLOGIQUES
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020123872A1

  公开（公告）日：2020-06-18

  The present invention relates to l-(2,6-diazaspiro[3.3]heptan-6- yl)-5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a][l,4]diazepine derivatives and related compounds of Formula (I): wherein A, B, G, R1, Rlb, RiC, R2 and X are as defined herein. The present compounds are vasopressin receptor antagonists (in particular of the Via receptor) for the treatment of neuro- psychological disorders, such as e.g. autism, anxiety, stress-related disorders, depression, schizophrenia or bipolar disorder. The present description discloses the synthesis of exemplary compounds, as well as pharmacological data thereof (e.g. pages 71 to 246; examples 1 to 49; tables 1 to 5). An exemplary compound is e.g. 8-chloro-l-(2-(5-fluoropyridin-2-yl) -2,6-diazaspiro[3.3]heptan-6-yl)-5-methyl-5,6-dihydro-4H-benzo[f] [l,2,4]triazolo[4,3-a][l,4]diazepine (example 1, compound no. 1).

  本发明涉及式(I)的l-(2,6-二氮杂螺[3.3]庚烷-6-基)-5,6-二氢-4H-苯并[f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷衍生物及相关化合物，其中A、B、G、R1、R1b、R1c、R2和X如本文所定义。本化合物是抗利尿激素受体拮抗剂（特别是Via受体）用于治疗神经心理障碍，例如自闭症、焦虑、与压力有关的障碍、抑郁症、精神分裂症或躁郁症。本说明揭示了示例化合物的合成，以及其药理数据（例如第71至246页；示例1至49；表1至5）。例如化合物为8-氯-l-(2-(5-氟吡啶-2-基)-2,6-二氮杂螺[3.3]庚烷-6-基)-5-甲基-5,6-二氢-4H-苯并[f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷（示例1，化合物编号1）。
• [EN] TRIAZOLE COMPOUNDS USEFUL IN THERAPY<br/>[FR] COMPOSES DE TRIAZOLE UTILISES EN THERAPIE
  申请人：PFIZER LTD

  公开号：WO2004074291A1

  公开（公告）日：2004-09-02

  A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents -(CH2)d(O)e-, -CO-, or -CH(C1-6 alkyl)-; W is -0-, -S(O)a , or -N(R1')-R1 represents H, C 1-6 alkyl, (CH2)bCOR2, CO(CH2)bNR2R3, S02R2, (CH2 )cOR2, (CH2)c,NR2R3, or (CH2)bhet1; het1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C 1-6 alkyl; X and Y independently represent H, C 1-6 alkyl, halogen, OH, CF3, OCF3, OR4; Z represents -(CH2)f(O)g , -CO- or -CH(C 1-6 alkyl)-; Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH2, CF3, OCF3, and in which optionally at least one ring N is substituted with O; R2 and R3 independently represent H, C 1-6 alkyl [optionally substituted with OH, halogen,N(C 1.6 alkyl)2, or C 1.6 alkyloxy], C 1.6 alkyloxy, N(C 1-6 alkyl)2, or [C 3-8 cycloalkyl]; or R2 and R3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C 1-6 alkyl;R4 represents straight or branched C 1-6 alkyl, a and c independently represent 0, 1, or 2; b, e and g independently represent 0 or 1; d and f independently represent 1 or 2;are useful in the treatment of dysmenorrhoea.

  式(I)的化合物，或其药学上可接受的衍生物，其中V代表-(CH2)d(O)e-, -CO-,或-CH(C1-6烷基)-；W为-0-, -S(O)a,或-N(R1')-R1代表H，C1-6烷基，(CH2)bCOR2，CO(CH2)bNR2R3，S02R2，(CH2)cOR2，(CH2)c,NR2R3，或(CH2)bhet1；het1代表一个饱和或不饱和的含有3至8个原子的杂环，其中含有一个或多个从O、N或S中选择的杂原子，可选择地用C1-6烷基取代；X和Y独立地代表H，C1-6烷基，卤素，OH，CF3，OCF3，或OR4；Z代表-(CH2)f(O)g，-CO-或-CH(C1-6烷基)-；环A代表一个4-7成员的饱和N-含杂环，可选择地用OH取代，并且其中可选择地至少一个环N用O取代；环B代表苯或一个4-7成员的不饱和N-含杂环，可选择地用OH，卤素，CN，CONH2，CF3，OCF3取代，并且其中可选择地至少一个环N用O取代；R2和R3独立地代表H，C1-6烷基[可选择地用OH，卤素，N(C1-6烷基)2，或C1-6烷氧基取代]，C1-6烷氧基，N(C1-6烷基)2，或[C3-8环烷基]；或R2和R3，连同它们附着的氮原子，独立地代表一个含有3至8个原子的杂环，可选择地用C1-6烷基取代；R4代表直链或支链C1-6烷基，a和c独立地代表0，1，或2；b，e和g独立地代表0或1；d和f独立地代表1或2；在痛经的治疗中是有用的。
• Triazole compounds useful in therapy
  申请人：Bryans Stephen Justin

  公开号：US20060194794A1

  公开（公告）日：2006-08-31

  A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  一种化合物的公式（I），或其药学上可接受的衍生物，其中A、B、V、W、X、Y和Z的定义如本文所述；其制药组合物；以及其用途。
• Vasopressin receptor antagonists and products and methods related thereto
  申请人：BlackThorn Therapeutics, Inc.

  公开号：US11186577B2

  公开（公告）日：2021-11-30

  Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.

  本研究提供了可拮抗血管加压素受体的化合物，特别是含有此类化合物的 V1a 受体产品，以及使用和合成此类化合物的方法。此类化合物具有式（I）结构，或其药学上可接受的异构体、外消旋体、水合物、溶液、同位素或盐： 其中 A、B、G、R1、R1b、R1c、R2 和 X 如本文所定义。
• Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues
  作者：Henry J. Breslin、Michael J. Kukla、Teresa Kromis、Heather Cullis、Fons De Knaep、Rudi Pauwels、Koen Andries、Erik De Clercq、Marcel A.C. Janssen、Paul A.J. Janssen

  DOI：10.1016/s0968-0896(99)00198-4

  日期：1999.11

  4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO), 1, have been shown to significantly inhibit HIV-1 replication, as reported in detail in our prior publications. Since our earlier reports, we have modified the TIBO structures 1 by removing the 5-membered ring of 1, generating 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-ones (TBO), 4, a bicyclic series of compounds. Although compounds 4 possess modest activity when compared to TIBO analogues 1, they clearly demonstrated significant anti-HIV-1 activity. (C) 1999 Elsevier Science Ltd. All rights reserved.